{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:04:28Z","timestamp":1776690268982,"version":"3.51.2"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T00:00:00Z","timestamp":1441756800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.neo.2015.09.001","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T01:56:43Z","timestamp":1445219803000},"page":"716-722","source":"Crossref","is-referenced-by-count":28,"title":["Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man\u2014PFS2: A Measure of Therapeutic Action-At-A-Distance"],"prefix":"10.1016","volume":"17","author":[{"given":"Bryan","family":"Oronsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey A.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony R.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Scicinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Oronsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Lybeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Caroen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meaghan","family":"Stirn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Oronsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Langecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.neo.2015.09.001_bb0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials","volume":"13","author":"Pazdur","year":"2008","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.neo.2015.09.001_bb0010","first-page":"22","article-title":"Translating cancer trial endpoints into the language of managed care","volume":"5","author":"Kogan","year":"2008","journal-title":"Biotechnol Health"},{"key":"10.1016\/j.neo.2015.09.001_bb0015","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: meaningful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2015.09.001_bb0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.neo.2015.09.001_bb0025","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3174\/ajnr.A2397","article-title":"Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma","volume":"32","author":"Hygino da Cruz","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"10.1016\/j.neo.2015.09.001_bb0030","first-page":"38","article-title":"Characteristics of computed tomography imaging of gastrointestinal stromal tumor (GIST) and related diagnostic problems","volume":"76","author":"Werewka-Maczuga","year":"2011","journal-title":"Pol J Radiol"},{"key":"10.1016\/j.neo.2015.09.001_bb0035","series-title":"ASCO Educational Book","first-page":"280","article-title":"Exploring Novel Immune-Related Toxicities and Endpoints with Immune-Checkpoint Inhibitors in Non\u2013Small Cell Lung Cancer","author":"Chow","year":"2013"},{"issue":"6","key":"10.1016\/j.neo.2015.09.001_bb0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrclinonc.2010.43","article-title":"Biomarkers and surrogate end points\u2014the challenge of statistical validation","volume":"7","author":"Buyse","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.neo.2015.09.001_bb0050","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrc3298","article-title":"Opinion: evolutionary dynamics of carcinogenesis and why targeted therapy does not work","volume":"12","author":"Gillies","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.neo.2015.09.001_bb0055","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.tranon.2014.08.003","article-title":"Rewriting the epigenetic code for tumor resensitization: a review","volume":"7","author":"Oronsky","year":"2014","journal-title":"Transl Oncol"},{"key":"10.1016\/j.neo.2015.09.001_bb0060","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1172\/JCI62423","article-title":"Alarmins: awaiting a clinical response","volume":"122","author":"Chan","year":"2012","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.neo.2015.09.001_bb0065","first-page":"387","article-title":"The war on cancer: a military perspective","volume":"26","author":"Oronsky","year":"2015","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/j.neo.2015.09.001_bb0070","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2008.20.4107","article-title":"Issues in using progression-free survival when evaluating oncology products","volume":"27","author":"Fleming","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.neo.2015.09.001_bb0075","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-012-2395-8","article-title":"Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology","volume":"138","author":"Garnett","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"10.1016\/j.neo.2015.09.001_bb0080","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2174\/1381612043384411","article-title":"Tumor intracellular redox status and drug resistance\u2014serendipity or a causal relationship?","volume":"10","author":"Pervaiz","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"10","key":"10.1016\/j.neo.2015.09.001_bb0085","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1158\/0008-5472.CAN-11-2303","article-title":"Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials","volume":"72","author":"Ning","year":"2012","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.neo.2015.09.001_bb0090","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-11-320093","article-title":"Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML","volume":"118","author":"Scandura","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.neo.2015.09.001_bb0095","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.6005.6005","article-title":"Time to second objective disease progression (PFS2): an emerging clinical trial endpoint with regulatory and reimbursement implications","volume":"124","author":"Mbanya","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.neo.2015.09.001_bb0100","first-page":"439","article-title":"Rationale for the use of alternating non\u2013cross-resistant chemotherapy","volume":"66","author":"Goldie","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.neo.2015.09.001_bb0105","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1200\/JCO.2009.24.5209","article-title":"Stop and go: yes or no?","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.neo.2015.09.001_bb0110","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","article-title":"Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study","volume":"27","author":"Chibaudel","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.neo.2015.09.001_bb0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1758834011431592","article-title":"Therapeutic strategy in unresectable metastatic colorectal cancer","volume":"4","author":"Tournigand","year":"2012","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.neo.2015.09.001_bb0120","first-page":"S17","article-title":"Optimising systemic therapy in metastatic colorectal cancer","volume":"16","author":"Hui","year":"2013","journal-title":"Hong Kong J Radiol"},{"issue":"8","key":"10.1016\/j.neo.2015.09.001_bb0125","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2174\/1871520614666140418144610","article-title":"Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment","volume":"14","author":"Oronsky","year":"2014","journal-title":"Anticancer Agents Med Chem"},{"issue":"7","key":"10.1016\/j.neo.2015.09.001_bb0130","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non\u2013small cell lung cancer","volume":"1","author":"Juergens","year":"2011","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.neo.2015.09.001_bb0150","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1007\/s12032-011-0016-8","article-title":"Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement","volume":"29","author":"Porta","year":"2012","journal-title":"Med Oncol"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558615001062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558615001062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T23:17:05Z","timestamp":1599693425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558615001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1476558615001062"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2015.09.001","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}